The combined JAK1/TYK2 inhibitor, SAR-20347, demonstrated in vitro and in vivo concentration-dependent reduction of IL-12, IL-22, and IFNγ-mediated inflammation and tissue pathology in the imiquimod-induced psoriasis model (129). This evidence concerns the gene IL22 and psoriasis.